Does ruxolitinib improve azacitidine's therapeutic success?

Does ruxolitinib boost azacitidine’s success in myelofibrosis?

Ruxolitinib combined with azacitidine improves spleen response rates and symptom scores over azacitidine alone in patients with myelofibrosis, based on a small early-phase study. The combination also reaches a higher rate of bone marrow fibrosis reduction compared with azacitidine monotherapy.

What happens when ruxolitinib is added to azacitidine in higher-risk myelodysplastic syndromes?

In a phase 2 trial, the two drugs together produced an overall response rate of 75% in treatment-naive patients and 54% in relapsed/refractory cases. Response duration averaged around 16 months, but survival data remain immature.

How does the ruxolitinib-azacitidine pair compare with ruxolitinib monotherapy?

The combination shows higher rates of spleen volume reduction and constitutional symptom relief than ruxolitinib alone, especially in patients whose symptoms persist on ruxolitinib. Data from cross-study comparisons indicate the dual therapy may address both proliferative and epigenetic pathways.

When does the ruxolitinib patent expire?

Ruxolitinib’s primary compound patent expires in the US in 2028. [1]